Ultragenyx sells Rare PRV for $210 million
Ultragenyx Pharmaceutical entered a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million, subject to customary closing conditions including expiration of the HSR waiting period.